BRINZOLAMIDE-1%W/VAgranulocytosis
How does the disease interact with Brinzoma Eye Drops 5ml:
Applying Brinzoma Eye Drops 5ml ophthalmic to the skin, eyes, or mucosal membranes may cause systemic absorption. In addition to methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anaemia, aplastic anaemia, purpura, coagulation problem, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia, the usage of sulfonamides has also been linked to hematologic damage. Patients who already have blood dyscrasias or marrow suppression should use topical sulfonamide therapy with caution. During prolonged therapy (>2 weeks), complete blood counts should be taken on a regular basis, and patients should be instructed to report any indications or symptoms of a blood dyscrasia right away, such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.
How to manage the interaction:
Brinzoma Eye Drops 5ml should be administered cautiously in patients with preexisting blood problems or bone marrow suppression. Complete blood count tests are advised regularly during prolonged therapy (>2 weeks). Consult the doctor if you notice signs or symptoms of blood problems such as fever, sore throat, local infection, bleeding, dizziness, or jaundice.
BRINZOLAMIDE-1%W/VDisorders of porphyrin and bilirubin metabolism
How does the disease interact with Brinzoma Eye Drops 5ml:
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. Patients with porphyria should use topical sulfonamide therapy with caution because these medications can cause an acute attack. Patients with porphyria are thought to be contraindicated for oral sulfonamide usage.
How to manage the interaction:
Therapy should be administered cautiously in patients with porphyria, since it may precipitate an acute attack.
BRINZOLAMIDE-1%W/VOther abnormal findings in urine
How does the disease interact with Brinzoma Eye Drops 5ml:
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. Due to the sulfonamide and/or its N4-acetyl metabolite precipitating in the urinary tract, the usage of sulfonamides has been linked to crystalluria. There have been reports of renal toxicity, including hematuria, proteinuria, increased BUN and creatinine, uro- and nephrolithiasis, nephritis, toxic nephrosis, and more. During the use of sulfonamides, hydration and sufficient urine output (> 1.5 L/day) should be maintained. Patients who are dehydrated (for instance, as a result of severe diarrhoea or vomiting) may be more vulnerable to developing crystalluria and lithiasis, thus they should be encouraged to drink more liquids.
How to manage the interaction:
Dehydrated patients may be at increased risk for the development of crystalluria and lithiasis (formation of stones). Therefore, consume additional amounts of liquid. Hydration and adequate urinary output (> 1.5 L/day) should be maintained during administration of the medicine. Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).
BRINZOLAMIDE-1%W/VOther diseases of liver
How does the disease interact with Brinzoma Eye Drops 5ml:
Rarely have individuals using sulfonamides reported experiencing hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis, and hepatic failure.
How to manage the interaction:
Therapy should be administered cautiously in patients with liver disease.
BRINZOLAMIDE-1%W/VOther disorders of kidney and ureter, not elsewhere classified
How does the disease interact with Brinzoma Eye Drops 5ml:
Sulfonamide side effects may be more likely to occur in those with renal impairment because of decreased medication clearance. Sulfonamides can also result in toxic nephrosis, hematuria, proteinuria, increased BUN, and creatinine levels in addition to renal damage related to crystalluria.
How to manage the interaction:
Hydration and adequate urinary output (> 1.5 L/day) should be maintained during administration of the medicine in patients with kidney dysfunction. Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).
BRINZOLAMIDE-1%W/VOther abnormal findings in urine
How does the disease interact with Brinzoma Eye Drops 5ml:
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. Hematologic toxicity has been linked to the usage of sulfonamides.
How to manage the interaction:
A urinary output of at least 1.5 L/day should be maintained during therapy. Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).